Latest Commercial Readiness News

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Provaris Energy has launched a fully funded Front End Engineering Design phase for its proprietary large-scale liquid CO2 tanks, backed by Yinson. The move signals growing market interest in scalable carbon capture shipping solutions, especially across Asia.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Provaris Energy has marked significant milestones in Q2 2025 with a key MOU with global shipping leader 'K' LINE and a joint venture formation with Yinson to commercialise proprietary hydrogen and carbon dioxide transport technologies.

Australian Vanadium Limited (AVL) reports strong progress on its integrated vanadium project, moving closer to final feasibility and advancing its utility-scale battery storage system, Project Lumina.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Carnegie Clean Energy has made significant strides in advancing its wave energy technologies, signing key MOUs and achieving critical milestones in the ACHIEVE Programme during the June 2025 quarter.

First Graphene Limited reports over A$1.2 million in annual income, driven by new commercial orders and breakthrough graphene applications in mining safety boots and cement additives.

Jindalee Lithium progresses its McDermitt Lithium Project with strong US government support and a promising new refining technology partnership, aiming to enhance sustainability and reduce costs.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.